



## AMDL-ELISA DR-70 (FDP) (branded as Onko-Sure®) Assay Description

The AMDL-ELISA DR-70 (FDP) test, is the most recent cancer test cleared by FDA for monitoring of treatment and recurrence of colorectal cancer and is branded as Onko-Sure®.

### Strategic Advantages

- Simple, non-invasive blood test
- Standard Sandwich ELISA format
- Clinically proven in 12 published studies for monitoring of colorectal cancer treatment and recurrence
- The blood biomarker is abundant in serum
- Floats-freely in blood (unlike CEA)
- Levels rise dramatically with cancer progression (up to 38 times greater than in normal patients)



### Onko-Sure® Assay Description

Standard sandwich-type Enzyme-Linked ImmunoSorbent Assay (ELISA). The antigen is captured from human serum samples by an affinity-purified rabbit anti-DR-70® (FDP) antibody that is immobilized in the wells of a standard 96-well assay plate. After appropriate washing, the antigen captured from the serum sample is complexed by a peroxidase-labeled detection antibody to form an immuno-sandwich. The bound enzyme conjugate is quantitatively measured with TMB substrate. Immediately after stopping the enzymatic reaction, the absorbance of the solution is read at 450 nm.